Hemab Therapeutics (NASDAQ:COAG) Stock Rating Upgraded by HC Wainwright

Hemab Therapeutics (NASDAQ:COAG) was upgraded by research analysts at HC Wainwright to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.

Several other analysts also recently commented on the stock. Evercore initiated coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price objective on the stock. Jefferies Financial Group initiated coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $39.00 price objective on the stock. The Goldman Sachs Group initiated coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price objective on the stock. Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Finally, Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Hemab Therapeutics presently has an average rating of “Buy” and a consensus target price of $41.40.

Hemab Therapeutics Trading Up 3.7%

Shares of COAG stock opened at $26.45 on Wednesday. Hemab Therapeutics has a one year low of $23.00 and a one year high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.

Insider Activity

In related news, major shareholder Ra Capital Management, L.P. purchased 61,523 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were purchased at an average price of $24.98 per share, with a total value of $1,536,844.54. Following the acquisition, the insider directly owned 6,444,637 shares in the company, valued at $160,987,032.26. The trade was a 0.96% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders have bought 2,970,541 shares of company stock worth $55,459,603.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.